Renee Maria Saliby, Postdoctoral GU Oncology Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“ TiNivo-2 answers a crucial question: is ICI-rechallenge the right thing to do in renal cell carcinoma?
The data says NO.
Great presentation by Toni Choueiri with concomitant publication in The Lancet Oncology.”
Source: Renee Maria Saliby/X
